Akari Therapeutics (AKTX) Short Interest Ratio & Short Volume $1.30 +0.06 (+4.84%) (As of 11/22/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Akari Therapeutics Short Interest DataAkari Therapeutics (AKTX) has a short interest of 21,300 shares, representing 0.18% of the float (the number of shares available for trading by the public). This marks a 15.14% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.3, indicating that it would take 1.3 days of the average trading volume of 20,796 shares to cover all short positions.Current Short Interest21,300 sharesPrevious Short Interest18,500 sharesChange Vs. Previous Month+15.14%Dollar Volume Sold Short$51,120.00Short Interest Ratio1.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares12,145,000 sharesFloat Size12,100,000 sharesShort Percent of Float0.18%Today's Trading Volume142,223 sharesAverage Trading Volume20,796 sharesToday's Volume Vs. Average684% Short Selling Akari Therapeutics? Sign up to receive the latest short interest report for Akari Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAKTX Short Interest Over TimeAKTX Days to Cover Over TimeAKTX Percentage of Float Shorted Over Time Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Akari Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202421,300 shares $51,120.00 +15.1%0.2%1.3 $2.40 10/15/202418,500 shares $47,191.65 -52.7%0.2%1.1 $2.55 9/30/202439,100 shares $115,345.00 -3.9%0.3%2.1 $2.95 9/15/202440,700 shares $132,478.50 +4.4%0.3%2.4 $3.26 8/31/202439,000 shares $149,370.00 +33.6%0.3%1.8 $3.83 8/15/202429,200 shares $93,440.00 +17.7%0.2%1.2 $3.20 Get the Latest News and Ratings for AKTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202424,800 shares $92,504.00 -0.4%0.3%1 $3.73 7/15/202424,900 shares $93,126.00 +236.5%0.3%1 $3.74 6/30/20247,400 shares $19,980.00 -53.2%0.1%0.3 $2.70 6/15/202415,800 shares $49,928.00 -26.9%0.2%0.6 $3.16 5/31/202421,600 shares $38,880.00 +71.4%0.3%0.9 $1.80 5/15/202412,600 shares $18,396.00 +472.7%0.2%0.7 $1.46 4/30/20242,200 shares $3,388.00 +266.7%0.0%0.1 $1.54 4/15/2024600 shares $720.00 -94.3%0.0%0.1 $1.20 3/31/202410,500 shares $19,582.50 +75.0%0.2%0.9 $1.87 3/15/20246,000 shares $11,820.00 -37.5%0.1%0.6 $1.97 2/29/20249,600 shares $21,216.00 +10.3%0.2%1.1 $2.21 2/15/20248,700 shares $20,706.00 +357.9%0.2%1 $2.38 1/31/20241,900 shares $4,807.00 -66.7%0.0%0.2 $2.53 1/15/20245,700 shares $16,416.00 +375.0%0.1%0.5 $2.88 12/31/20231,200 shares $3,744.00 -29.4%0.0%0.1 $3.12 12/15/20231,700 shares $4,760.00 -50.0%0.0%0.1 $2.80 11/30/20233,400 shares $10,030.00 -69.6%0.1%0.3 $2.95 11/15/202311,200 shares $35,504.00 -36.0%0.2%0.7 $3.17 10/31/202317,500 shares $61,425.00 +49.6%0.4%0.8 $3.51 10/15/202311,700 shares $42,705.00 -33.5%0.2%0.4 $3.65 9/30/202317,600 shares $69,520.00 +2.9%0.4%0.7 $3.95 9/15/202317,100 shares $62,244.00 +116.5%0.5%0.6 $3.64 8/31/20237,900 shares $24,885.00 -24.8%0.2%0.3 $3.15 8/15/202310,500 shares $39,585.00 -95.7%0.3%0.3 $3.77 7/31/2023243,800 shares $60,852.48 -29.2%N/A0.5 $0.25 7/15/2023344,200 shares $58,961.46 +67.3%N/A0.6 $0.17 6/30/2023205,700 shares $34,948.43 -1.5%N/A0.4 $0.17 6/15/2023208,800 shares $32,760.72 -3.7%N/A0.4 $0.16 5/31/2023216,700 shares $38,334.23 -5.2%N/A0.4 $0.18 5/15/2023228,600 shares $42,153.84 +104.5%N/A0.5 $0.18 4/30/2023111,800 shares $20,246.98 -62.3%N/A0.3 $0.18 4/15/2023296,900 shares $59,409.69 +128.0%N/A0.8 $0.20 3/31/2023130,200 shares $23,657.34 -21.5%N/A0.5 $0.18 3/15/2023165,800 shares $42,776.40 +79.4%N/A1.3 $0.26Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. 2/28/202392,400 shares $31,878.00 +42.2%N/A0.8 $0.35 2/15/202365,000 shares $29,250.00 -30.6%N/A0.7 $0.45 1/31/202393,700 shares $43,739.16 -15.9%N/A1.2 $0.47 1/15/2023111,400 shares $60,111.44 +47.2%N/A1.4 $0.54 12/30/202275,700 shares $35,571.43 -2.1%N/A0.9 $0.47 12/15/202277,300 shares $35,558.00 -43.0%N/A1 $0.46 11/30/2022135,500 shares $74,877.30 -8.2%N/A1.3 $0.55 11/15/2022147,600 shares $84,279.60 +313.5%N/A1.5 $0.57 10/31/202235,700 shares $16,629.06 -44.8%N/A0.4 $0.47 10/15/202264,700 shares $31,470.08 -16.8%N/A0.7 $0.49 9/30/202277,800 shares $49,014.00 +215.0%0.5%0.8 $0.63 9/15/202224,700 shares $16,796.00 -10.5%0.2%0.3 $0.68 8/31/202227,600 shares $32,844.00 -47.1%0.2%0.4 $1.19 8/15/202252,200 shares $78,300.00 +1,435.3%0.4%0.7 $1.50 7/31/20223,400 shares $3,876.00 -95.0%0.0%0 $1.14 7/15/202267,300 shares $56,585.84 -10.7%0.5%1.1 $0.84 6/30/202275,400 shares $75,400.00 -30.1%0.5%1.4 $1.00 6/15/2022107,900 shares $104,663.00 -16.6%0.8%2 $0.97 5/31/2022129,300 shares $151,281.00 +35.8%N/A2.1 $1.17 5/15/202295,200 shares $104,720.00 +12.4%N/A1.5 $1.10 4/30/202284,700 shares $100,793.00 +4.6%N/A1.2 $1.19 4/15/202281,000 shares $97,200.00 -13.0%N/A1.1 $1.20 3/31/202293,100 shares $111,720.00 -12.3%N/A1.2 $1.20 3/15/2022106,200 shares $117,351.00 +14.9%N/A1 $1.11 2/28/202292,400 shares $124,740.00 -3.3%N/A0.9 $1.35 2/15/202295,500 shares $146,115.00 +24.8%N/A1 $1.53 1/31/202276,500 shares $104,805.00 -11.1%N/A0.8 $1.37 1/15/202286,000 shares $124,700.00 -40.5%N/A0.8 $1.45 12/31/2021144,500 shares $216,750.00 +113.4%N/A1.3 $1.50 12/15/202167,700 shares $101,570.31 +129.5%N/A0.7 $1.50 11/30/202129,500 shares $48,085.00 +87.9%N/A0.3 $1.63 11/15/202115,700 shares $25,905.00 -74.4%N/A0.1 $1.65 10/29/202161,300 shares $101,758.00 +48.8%N/A0.6 $1.66 10/15/202141,200 shares $67,980.00 -11.0%N/A0.4 $1.65 9/30/202146,300 shares $75,469.00 -38.8%N/A0.4 $1.63 9/15/202175,700 shares $139,288.00 +90.7%N/A0.7 $1.84 8/31/202139,700 shares $73,048.00 -2.0%N/A0.3 $1.84 8/13/202140,500 shares $67,635.00 -17.9%N/A0.3 $1.67 7/30/202149,300 shares $79,866.00 -40.8%N/A0.3 $1.62 7/15/202183,200 shares $137,280.00 +51.6%N/A0.2 $1.65 6/30/202154,900 shares $94,977.00 -43.6%N/A0.1 $1.73 6/15/202197,300 shares $170,275.00 +72.5%N/A0.2 $1.75 5/28/202156,400 shares $101,238.00 -39.6%N/A0.1 $1.80 5/14/202193,300 shares $167,940.00 -59.2%N/A0.2 $1.80 4/30/2021228,400 shares $477,356.00 +217.7%N/A0.5 $2.09 4/15/202171,900 shares $154,585.00 +276.4%N/A0.3 $2.15 3/31/202119,100 shares $48,514.00 -77.3%N/A0.1 $2.54 3/15/202184,200 shares $262,704.00 +231.5%N/A0.4 $3.12 2/26/202125,400 shares $84,328.00 -28.1%N/A0.1 $3.32 2/12/202135,300 shares $96,016.00 -77.7%N/A0.1 $2.72Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. 1/29/2021158,000 shares $379,200.00 -16.8%N/A0.6 $2.40 1/15/2021189,800 shares $482,092.00 +10.3%N/A0.7 $2.54 12/31/2020172,100 shares $313,222.00 +10.8%N/A0.9 $1.82 12/15/2020155,300 shares $301,282.00 +119.0%N/A0.9 $1.94 11/30/202070,900 shares $111,313.00 +24.8%N/A0.5 $1.57 11/15/202056,800 shares $92,016.00 -15.0%N/A0.4 $1.62 10/30/202066,800 shares $106,212.00 -39.6%N/A0.5 $1.59 10/15/2020110,500 shares $202,215.00 -29.8%N/A0.6 $1.83 9/30/2020157,400 shares $273,876.00 -42.1%N/A0.8 $1.74 9/15/2020272,000 shares $465,120.00 +19.5%N/A1 $1.71 8/31/2020227,700 shares $391,644.00 +3.6%N/A0.7 $1.72 8/14/2020219,700 shares $417,430.00 +34.6%N/A0.6 $1.90 7/31/2020163,200 shares $328,032.00 +4.0%N/A0.4 $2.01 7/15/2020157,000 shares $312,430.00 +90.1%N/A0.4 $1.99 6/30/202082,600 shares $186,676.00 -56.7%N/A0.2 $2.26 6/15/2020190,900 shares $376,073.00 +186.2%N/A0.7 $1.97 5/29/202066,700 shares $133,400.00 -35.8%N/A0.3 $2.00 5/15/2020103,900 shares $180,786.00 -11.1%N/A0.6 $1.74 4/30/2020116,900 shares $224,448.00 -11.1%N/A0.9 $1.92 4/15/2020131,500 shares $203,825.00 -33.6%N/A1.2 $1.55 3/31/2020198,100 shares $334,789.00 +45.7%N/A1 $1.69 3/13/2020136,000 shares $204,000.00 -13.8%N/A0.9 $1.50 2/28/2020157,700 shares $200,279.00 -21.3%N/A0.7 $1.27 2/14/2020200,300 shares $332,498.00 -3.3%N/A0.6 $1.66 1/31/2020207,100 shares $395,561.00 -37.1%N/A0.6 $1.91 1/15/2020329,100 shares $608,835.00 -25.6%N/A0.9 $1.85 12/31/2019442,400 shares $818,440.00 +48.4%N/A1.2 $1.85 AKTX Short Interest - Frequently Asked Questions What is Akari Therapeutics' current short interest? Short interest is the volume of Akari Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 21,300 shares of AKTX short. 0.18% of Akari Therapeutics' shares are currently sold short. Learn More on Akari Therapeutics' current short interest. What is a good short interest ratio for Akari Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKTX shares currently have a short interest ratio of 1.0. Learn More on Akari Therapeutics's short interest ratio. What is a good short interest percentage for Akari Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.18% of Akari Therapeutics' floating shares are currently sold short. Is Akari Therapeutics' short interest increasing or decreasing? Akari Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 21,300 shares, an increase of 15.1% from the previous total of 18,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Akari Therapeutics' float size? Akari Therapeutics currently has issued a total of 12,145,000 shares. Some of Akari Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Akari Therapeutics currently has a public float of 12,100,000 shares. How does Akari Therapeutics' short interest compare to its competitors? 0.18% of Akari Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Akari Therapeutics: Cocrystal Pharma, Inc. (0.03%), CervoMed Inc. (27.66%), OptiNose, Inc. (5.68%), Entera Bio Ltd. (0.12%), Mural Oncology plc (2.62%), Aadi Bioscience, Inc. (1.57%), Aileron Therapeutics, Inc. (1.19%), Theratechnologies Inc. (0.23%), Kezar Life Sciences, Inc. (2.87%), Unicycive Therapeutics, Inc. (1.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Akari Therapeutics stock? Short selling AKTX is an investing strategy that aims to generate trading profit from Akari Therapeutics as its price is falling. AKTX shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akari Therapeutics? A short squeeze for Akari Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AKTX, which in turn drives the price of the stock up even further. How often is Akari Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKTX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies COCP Short Interest CRVO Short Interest OPTN Short Interest ENTX Short Interest MURA Short Interest AADI Short Interest ALRN Short Interest THTX Short Interest KZR Short Interest UNCY Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKTX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
